LEUCID BIO
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.
LEUCID BIO
Social Links:
Industry:
Biotechnology
Founded:
2014-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.leucid.com
Total Employee:
11+
Status:
Active
Total Funding:
11.5 M GBP
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Wix Hosted
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Epidarex Capital
Epidarex Capital investment in Series A - Leucid Bio
2invest
2invest investment in Series A - Leucid Bio
Sofinnova Partners
Sofinnova Partners investment in Series A - Leucid Bio
Vulpes Investment Management Pte Ltd
Vulpes Investment Management Pte Ltd investment in Series A - Leucid Bio
British Business Bank
British Business Bank investment in Series A - Leucid Bio
Official Site Inspections
http://www.leucid.com
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Leucid Bio"
Home | Leucid bio
Our mission is to develop next generation CAR-T therapies using the Company’s proprietary Lateral CAR platform to improve treatment outcomes and save the lives of patients with …See details»
About us - Leucid bio
Leucid Bio is a clinical stage biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR Platform to improve treatment …See details»
News - Leucid bio
Leucid Bio is a biotechnology company developing novel, Lateral CAR cell therapies for the treatment of refractory cancers. Leucid was established to translate 20 years of King's College London research in the CAR-T field and is …See details»
Leucid Bio - Crunchbase Company Profile & Funding
Leucid is progressing novel cart therapies that produce a better and more durable response. View contacts for Leucid Bio to access new leads and connect with decision-makers. Leucid Bio is a pioneering biotech company developing cell …See details»
Leucid Bio - LinkedIn
Thinking laterally about CAR-T. Develops Autologous and Allogeneic cell and gene Therapies for hard to treat cancers. Leucid is progressing novel CAR T therapies that produce a better and more...See details»
Leucid Bio Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Leucid Bio. Use the PitchBook Platform to explore the full profile.See details»
pCAR technology: an interview with John Maher — …
Mar 25, 2022 · LEU-011 builds on Leucid’s pCAR platform and is targeted against a family of stress-induced molecules known as NKG2D ligands. Since tumors are sites of intense cell stress, NKG2D ligands are widely expressed on both solid …See details»
UK startup Leucid raises £11.5m for solid tumour CAR-T therapies
Oct 21, 2021 · UK startup Leucid Bio hopes to change that – and has just raised £11.5 million in first-round financing to take its plans forward. The London-based biotech has been set up to …See details»
Artin Moussavi - Chief Business Officer at Leucid Bio - The Org
In 2019, Artin became the Chief Executive Officer of Leucid Bio, a company pioneering the development of CAR T-cell therapies for cancer treatment. Artin is currently the Chief …See details»
London-based biotech Leucid Bio raises £11.5M funding for hard …
Oct 25, 2021 · Based out of London, Leucid Bio is a pioneering biotech company working on next-generation cell therapies for hard-to-treat cancers. Recently, the company announced that it …See details»
Leucid Bio Raises £11.5M in Series A Financing to Develop Next ...
LONDON, Oct. 21, 2021 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces …See details»
LEUCID BIO - VentureRadar
Website: http://www.leucid.com/ Develops cell therapies for refractory cancers, focusing on solid tumors, leveraging exclusive access to King's College London's immuno-oncology expertise …See details»
Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the ...
LONDON, Dec. 2, 2021 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces …See details»
Pipeline - Leucid bio
Using its proprietary Lateral CAR platform, Leucid Bio has developed a pipeline of assets for the treatment of solid tumours and haematological malignancies.See details»
Leucid Bio raises £11.5 million to develop CAR-T cell therapies
Oct 25, 2021 · Leucid Biohas raised £11.5 million in a Series A financing round, which will be used to initiate a Phase I trial of its lead candidate, LEU-011, for the treatment of platinum …See details»
Leucid Bio Chief Scientific Officer John Maher publishes new …
Mar 16, 2022 · Leucid's LEU-011 programme is a NKG2D-targeted pCAR T-cell therapy in pre-clinical development for the treatment of solid tumours and haematological malignancies. LEU …See details»
Leucid Bio taps Lonza's production expertise for a phase 1 CAR-T ...
Dec 2, 2021 · Lonza and Leucid Bio have inked a collaboration deal that will see the Swiss CDMO giant responsible for manufacturing CAR-T therapies for the London biotech’s upcoming …See details»
Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the ...
Dec 2, 2021 · Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of platinum resistant ovarian …See details»
With series A backing, Leucid heads for clinic with third ... - BioWorld
One of those is London-based Leucid Bio Ltd., which has just raised £11.5 million (nearly US$16 million) in series A financing to develop next-generation CAR T therapies that are able to make …See details»
LEU-004 - Drug Targets, Indications, Patents - Synapse - Patsnap
Now, its global highest R&D status is Preclinical, Mechanism: Gene transference,T lymphocyte replacements, Therapeutic Areas: Neoplasms,Hemic and Lymphatic Diseases, Active …See details»